NCT05819138View on ClinicalTrials.gov

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

October 1, 2027

Study Completion Date

December 1, 2027

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Semaglutide Pen Injector

Semaglutide injection

DRUG

Placebo

Semaglutide placebo injection

Trial Locations (2)

80045

RECRUITING

University of Colorado Anschutz Medical Campus, Aurora

98109

RECRUITING

University of Washington Medicine Diabetes Institute (UWMDI), Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Colorado, Denver

OTHER